Susquehanna analyst Shyam Patil downgrades Roku (NASDAQ:ROKU) from Positive to Neutral and lowers the price target from $200 to $70.
Analyst Ratings for 4D Molecular Therapeutics
Within the last quarter, 4D Molecular Therapeutics (NASDAQ:FDMT) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent…